Summary
This study aims to test a new way to deliver radiation therapy to people with cancer that has spread to their bones to enhance local control of metastatic lesions while maintaining acceptable toxicity profiles.
Who is it for?
You may be eligible to join this study if you are aged 18 years and older, are with Pathological diagnosis of a solid tumour, no planned change to main medication on the first day of protocol radiation therapy. You must have an imaging confirmed bone metastases and an estimated life expectancy greater than 3 months. Germ cell tumours and small-cell cancers are excluded.
Study details
All participants who meet the eligibility criteria in this study will be given treatment either:
- once a day for 5 days over 1 week, or
- once a day for 10 days over 2 weeks (Monday to Friday, with weekends off unless needed).
The treatment includes a standard radiation dose to the affected bone area, along with a more focused, higher-density boost to the main tumour area using advanced imaging. This boost is designed to better target the cancer while protecting healthy tissue.
During and after completion of the treatment, participants will be assessed for pain response and patient outcomes using questionnaires, fractures using imaging, and need for re-irradiation and salvage surgery to treatment sites through clinical follow-up and medical review.
It is hoped that this research project will help determine if this combined approach is safe, effective, and practical to deliver in routine care to improve pain relief and tumour control while keeping side effects low.